No detectable impact of short-term treatment delays on lung cancer survival
Authors:
Open Access
- 7 May 2025
- journal article
- research article
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 793-805
Abstract
Timely initiation of treatment is a core principle of oncologic care, especially for aggressive cancers such as lung cancer. However, the real-world impact of short-term delays in treatment initiation on survival outcomes in lung cancer remains unclear. This meta-analysis evaluates the association between treatment delays of 4, 8, and 12 weeks and all-cause mortality in lung cancer patients. A systematic search was conducted in PubMed, Scopus, and Web of Science for studies published between 2000 and 2025. Of 5360 screened records, 15 studies were included, comprising 16 cohorts for overall survival of lung cancer patients. Hazard ratios (HRs) for 4-, 8-, and 12-week treatment delays were estimated using random-effects meta-analyses. Heterogeneity was measured with the I 2 statistic, and publication bias was assessed using funnel plots and Egger’s test. No significant association was found between treatment delay and survival at any of the time points. Pooled HRs were 1.00 (95% CI, 0.99–1.02) for a 4-week delay, 1.01 (95% CI, 0.99–1.03) for an 8-week delay, and 1.01 (95% CI, 0.98–1.05) for a 12-week delay. Despite high heterogeneity ( I 2 = 97%), no evidence of publication bias was detected. This meta-analysis found no significant impact of short-term treatment delays (up to 12 weeks) on mortality in lung cancer patients. These findings challenge the assumption that brief delays universally worsen outcomes and underscore the importance of individualized treatment planning and prioritization.Keywords
Funding Information
- Semmelweis University
This publication has 73 references indexed in Scilit:
- Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non–Small Cell Lung CancerJAMA Network Open, 2021
- Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer SurgeryJAMA Oncology, 2017
- Time to Surgery and Breast Cancer Survival in the United StatesJAMA Oncology, 2016
- Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/EthnicityJAMA Surgery, 2013
- Time to adjuvant chemotherapy and survival in non–small cell lung cancerCancer, 2012
- Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, CanadaCancer, 2011
- Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?Cancer, 2010
- Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based StudyDiseases of the Colon & Rectum, 2010
- Etiology of Delays in the Initiation of Adjuvant Chemotherapy and Their Impact on Outcomes for Stage II and III Rectal CancerDiseases of the Colon & Rectum, 2009
- Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancerCancer, 2006